pyrroles has been researched along with Arterial Occlusive Diseases in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alhussaini, AA; Bogaard, HJ; Cool, CD; Drake, JI; Farkas, D; Farkas, L; Kraskauskas, D; Kraskauskiene, V; Voelkel, NF | 1 |
| Bregar, U; Jug, B; Poredos, P; Sabovic, M; Sebestjen, M | 1 |
| Bellmunt, J; Choueiri, TK; Je, Y; Rosenberg, JE; Schutz, FA | 1 |
| Minor, DR | 1 |
| Kröger, K; Wittlinger, T | 1 |
| Bucek, RA; Minar, E; Pourazim, A; Reiter, M; Wirth, S | 1 |
| El Menjawi, I; Fladerer, P; Krause, R; Pohanka, E; Wenisch, C | 1 |
| Criqui, MH | 1 |
| Griffith, TM; Randall, MD | 1 |
| Angerbach, D; Nicholson, CD | 1 |
3 review(s) available for pyrroles and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Arterial Occlusive Diseases; Benzenesulfonates; Humans; Incidence; Indoles; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thromboembolism | 2010 |
[Role of lipid lowering therapy in patients with peripheral arterial occlusive disease].
Topics: Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Disease Progression; Exercise Test; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Jejunoileal Bypass; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2004 |
Systemic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arterial Occlusive Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Survival Rate | 2001 |
1 trial(s) available for pyrroles and Arterial Occlusive Diseases
| Article | Year |
|---|---|
The influence of atorvastatin on walking performance in peripheral arterial disease.
Topics: Aged; Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Cholesterol, LDL; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Double-Blind Method; Exercise Test; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Intermittent Claudication; Male; Middle Aged; Pyrroles; Statistics, Nonparametric; Walking | 2009 |
6 other study(ies) available for pyrroles and Arterial Occlusive Diseases
| Article | Year |
|---|---|
CXCR4 inhibition ameliorates severe obliterative pulmonary hypertension and accumulation of C-kit⁺ cells in rats.
Topics: Actins; Analysis of Variance; Animals; Arterial Occlusive Diseases; Benzylamines; Cyclams; Fluorescent Antibody Technique; Heterocyclic Compounds; Hypertension, Pulmonary; Immunohistochemistry; In Situ Hybridization; Indoles; Microscopy, Confocal; Proto-Oncogene Proteins c-kit; Pyrroles; Rats; Receptors, CXCR4; von Willebrand Factor | 2014 |
Risk of arterial thrombosis not increased by sorafenib or sunitinib.
Topics: Angiogenesis Inhibitors; Arterial Occlusive Diseases; Benzenesulfonates; Evidence-Based Medicine; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Reproducibility of Results; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thromboembolism | 2010 |
Influence of HMG-CoA-reductase inhibitors on the body fat status.
Topics: Adipose Tissue; Aged; Arterial Occlusive Diseases; Atorvastatin; Body Composition; Body Mass Index; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Simvastatin | 2006 |
Acute rhabdomyolysis after atorvastatin and fusidic acid therapy.
Topics: Acute Disease; Aged; Angioplasty, Balloon; Anti-Bacterial Agents; Arterial Occlusive Diseases; Atorvastatin; Drug Therapy, Combination; Fusidic Acid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Pyrroles; Rhabdomyolysis; Risk Factors; Surgical Wound Infection; Tibial Arteries | 2000 |
Effects of BRL 38227, sodium nitroprusside and verapamil on collateral perfusion following acute arterial occlusion in the rabbit isolated ear.
Topics: Animals; Arginine; Arterial Occlusive Diseases; Benzopyrans; Cromakalim; Ear, External; In Vitro Techniques; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitroprusside; Pyrroles; Rabbits; Regional Blood Flow; Vasodilation; Vasodilator Agents; Verapamil | 1992 |
Enhancement of muscle blood cell flux and pO2 by cromakalim (BRL 34915) and other compounds enhancing membrane K+ conductance, but not by Ca2+ antagonists or hydralazine, in an animal model of occlusive arterial disease.
Topics: Animals; Antihypertensive Agents; Arterial Occlusive Diseases; Benzopyrans; Calcium Channel Blockers; Cell Membrane; Cromakalim; Hydralazine; In Vitro Techniques; Male; Muscles; Oxygen Consumption; Potassium; Pyrroles; Rats; Rats, Inbred Strains; Regional Blood Flow | 1988 |